ECRI Institute Introduces The Evidence Bar

By
With just 10 emplyees and a shared office space in West Connshohocken, Madrigal Pharmaceuticals has experiennced a surge in its stock price thanks to successful testing of its new method for treating nonalcoholic steatohepatitis. (MONTCO.Today file photo.)

ECRI Institute is giving healthcare payers and providers an unbiased overview of the evidence on new and emerging name-brand drugs and devices through ‘The Evidence Bar.’

“With our new Evidence Bar and restructured summary format, health professionals can now more quickly and confidently inform their decisions on new and emerging interventions,” said Vivian H. Coates, MBA, Vice President of Health Technology Assessment at ECRI Institute.

The Evidence Bar is the institute’s proprietary approach for evaluating the benefits and side-effects of a name-brand drug or device. According to Diane C. Robertson, Director of Health Technology Assessment at ECRI Institute, the evidence available for a certain drug or device often does not address all key questions and is rarely conclusive.

“Whereas others may assign a low rating to inconclusive evidence, implying that one should disregard the technology, The Evidence Bar signals payers and providers to proceed with caution and stay tuned for more developments,” she said.

[uam_ad id=”51711″]

Advertisement